Psoriasis: brodalumab safety, efficacy independent of BMI

  • Hsu S & al.
  • Br J Dermatol
  • 5 Jul 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Brodalumab is associated with similar efficacy in patients with moderate to severe psoriasis with BMI ≥30 vs 2.

Why this matters

  • Obesity is often expected to negatively affect therapeutic response in this population.

Key results

  • Brodalumab efficacy was similar between patients with BMI ≥30 vs 2.
    • At 12 weeks: ≥75% improvement in Psoriasis Area and Severity Index (PASI-75), 97.8% vs 97.5%; PASI-100, 49.5% vs 54.1%.
    • At 52 weeks: PASI-75, 93.4% vs 87.3%; PASI-100, 64.8% vs 72.6%.
  • Brodalumab was associated with higher PASI-100 rates than ustekinumab at 12 weeks in patients with BMI ≥30 kg/m2 (P=.001) and patients with BMI 2 (P=.002), and at 52 weeks in patients with BMI 2 (P=.002).
  • Serious adverse event rates were similar between patients treated with brodalumab with BMI ≥30 g/m2 vs those with BMI 2.

Study design

  • 687 patients with moderate to severe psoriasis, 40.9% with BMI ≥30 g/m2, were included.
  • 248 patients received continuous brodalumab, 316 received continuous ustekinumab, and 123 initially receiving ustekinumab received rescue therapy with brodalumab because of the lack of clinical response.
  • Funding: Ortho Dermatologics; Amgen Inc.

Limitations

  • Post hoc analysis not powered to evaluate differences in efficacy or safety based on BMI category.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit